-
Article
Open AccessMulti-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study
The evaluation of measurable residual disease (MRD) in acute myeloid leukemia (AML) using comprehensive mutation analysis by next-generation sequencing (NGS) has been investigated in several studies. However c...
-
Article
Open AccessPrognostic impact of CEBPA mutational subgroups in adult AML
Despite recent refinements in the diagnostic and prognostic assessment of CEBPA mutations in AML, several questions remain open, i.e. implications of different types of basic region leucin zipper (bZIP) mutations...
-
Article
Open AccessGlasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial
This is the primary report of the randomized, placebo-controlled phase 3 BRIGHT AML 1019 clinical trial of glasdegib in combination with intensive chemotherapy (cytarabine and daunorubicin) or non-intensive ch...
-
Article
Open AccessTREC mediated oncogenesis in human immature T lymphoid malignancies preferentially involves ZFP36L2
The reintegration of excised signal joints resulting from human V(D)J recombination was described as a potent source of genomic instability in human lymphoid cancers. However, such molecular events have not be...
-
Article
Open AccessUBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia
Tandem duplications (TDs) of the UBTF gene have been recently described as a recurrent alteration in pediatric acute myeloid leukemia (AML). Here, by screening 1946 newly diagnosed adult AML, we found that UBTF-T...
-
Article
Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis
Hyperleukocytosis is associated with a significant early mortality rate in patients with acute myeloid leukemia (AML). To date, no controlled trial has ever evaluated a strategy to reduce this risk, and the in...
-
Article
Open AccessHarnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL
The acquisition of genetic abnormalities engendering oncogene dysregulation underpins cancer development. Certain proto-oncogenes possess several dysregulation mechanisms, yet how each mechanism impacts clinic...
-
Article
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
The real-world efficacy and safety of gilteritinib was assessed in an ambispective study that included 167 R/R FLT3-mutated AML patients. Among them, 140 received gilteritinib as single agent (cohort B), includin...
-
Article
Open AccessPublisher Correction: Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r
-
Article
Open AccessFrugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r
Internal tandem duplications in the FLT3 gene, termed FLT3-ITDs, are useful molecular markers in acute myeloid leukemia (AML) for patient risk stratification and follow-up. FLT3-ITDs are increasingly screened thr...
-
Article
Open AccessA multiparametric niche-like drug screening platform in acute myeloid leukemia
Functional precision medicine in AML often relies on short-term in vitro drug sensitivity screening (DSS) of primary patient cells in standard culture conditions. We designed a niche-like DSS assay combining p...
-
Article
Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia
By querying metabolic pathways associated with leukemic stemness and survival in multiple AML datasets, we nominated SLC7A11 encoding the xCT cystine importer as a putative AML dependency. Genetic and chemical in...
-
Article
A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia
The treatment landscape of acute myeloid leukemia (AML) is evolving, with promising therapies entering clinical translation, yet patient responses remain heterogeneous, and biomarkers for tailoring treatment a...
-
Article
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML
The independent prognostic impact of specific dysplastic features in acute myeloid leukemia (AML) remains controversial and may vary between genomic subtypes. We apply a machine learning framework to dissect t...
-
Article
Open AccessClinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins
T-cell acute lymphoblastic leukemias (T-ALL) represent 15% of pediatric and 25% of adult ALL. Since they have a particularly poor outcome in relapsed/refractory cases, identifying prognosis factors at diagnosi...
-
Article
Open AccessAuthor Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
-
Article
Open AccessGenome-wide association study identifies susceptibility loci for acute myeloid leukemia
Acute myeloid leukemia (AML) is a hematological malignancy with an undefined heritable risk. Here we perform a meta-analysis of three genome-wide association studies, with replication in a fourth study, incorp...
-
Article
Open AccessOutcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia
The phase 3 ALFA-0701 trial demonstrated improved outcomes with fractionated-dose gemtuzumab ozogamicin (GO) combined with standard chemotherapy vs. standard chemotherapy alone in adults with de novo acute mye...
-
Article
Open AccessOncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL
IDH1 and IDH2 mutations (IDH1/2Mut) are recognized as recurrent genetic alterations in acute myeloid leukemia (AML) and associated with both clinical impact and therapeutic opportunity due to the recent developme...
-
Article
Open AccessA transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis
Classification of acute lymphoblastic and myeloid leukemias (ALL and AML) remains heavily based on phenotypic resemblance to normal hematopoietic precursors. This framework can provide diagnostic challenges fo...
